title: [Effect of Jinlida on changes in expression of skeletal muscle lipid transport enzymes in fat-induced insulin resistance ApoE -/- mice].
abstract: OBJECTIVE
  To study the effect of Jinlida on changes in expression of skeletal muscle lipid transport enzymes in fat-induced insulin resistance ApoE -/- mice.
  
  
  METHODS
  Eight male C57BL/6J mice were selected in the normal group (NF), 40 male ApoE -/- mice were fed for 16 weeks, divided into the model group (HF), the rosiglitazone group ( LGLT), the Jinlida low-dose group (JLDL), the Jinlida medium-dose group (JLDM), the Jinlida high-dose group (JLDH) and then orally given drugs for 8 weeks. The organization free fatty acids, BCA protein concentration determination methods were used to determine the skeletal muscle FFA content. The Real-time fluorescent quantitative reverse transcription PCR ( RT-PCR) and Western blot method were adopted to determine mRNA and protein expressions of mice fatty acids transposition enzyme (FAT/CD36), carnitine palm acyltransferase 1 (CPT1), peroxide proliferators-activated receptor α( PPAR α).
  
  
  RESULTS
  Jinlida could decrease fasting blood glucose (FBG), cholesterol (TC), triglyceride (TG), free fatty acid (FFA) and fasting insulin (FIns) and raise insulin sensitive index (ISI) in mice to varying degrees. It could also up-regulate mRNA and protein expressions of CPT1 and PPARα, and down-regulate mRNA and protein levels of FAT/CD36.
  
  
  CONCLUSIONS
  Jinlida can improve fat-induced insulin resistance ApoE -/- in mice by adjusting the changes in expression of skeletal muscle lipid transport enzymes.
authors.forename: Xin
authors.initials: X
authors.lastname: Jin
authors.forename: Hui-xin
authors.initials: HX
authors.lastname: Zhang
authors.forename: Yan-fen
authors.initials: YF
authors.lastname: Zhang
authors.forename: Wen-wen
authors.initials: WW
authors.lastname: Cui
authors.forename: Yao
authors.initials: Y
authors.lastname: Bi
authors.forename: Qi-long
authors.initials: QL
authors.lastname: He
authors.forename: Sheng-shan
authors.initials: SS
authors.lastname: Zhou
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics*; D001786:Blood Glucose / Q000378:metabolism; D018955:CD36 Antigens / Q000235:genetics* / Q000378:metabolism; D002334:Carnitine O-Palmitoyltransferase / Q000235:genetics* / Q000378:metabolism; D004041:Dietary Fats / Q000009:adverse effects / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*
chemical_list: D001057:Apolipoproteins E; D001786:Blood Glucose; D018955:CD36 Antigens; D004041:Dietary Fats; D004365:Drugs, Chinese Herbal; D007004:Hypoglycemic Agents; D007328:Insulin; D002334:Carnitine O-Palmitoyltransferase